• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.

作者信息

Ottaiano Alessandro, Nasti Guglielmo, Cassata Antonino, De Stefano Alfonso, Caraglia Michele, Avallone Antonio

机构信息

Department of Abdominal Oncology, National Cancer Institute of Naples, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Via Mariano Semmola, 80131, Naples, Italy.

Department of Biochemistry, Biophysics and General Pathology. University of Campania "L. Vanvitelli" of Naples, Via De Crecchio 7, 80127, Naples, Italy.

出版信息

Cancer Lett. 2017 Nov 1;408:71-72. doi: 10.1016/j.canlet.2017.08.025. Epub 2017 Aug 24.

DOI:10.1016/j.canlet.2017.08.025
PMID:28844712
Abstract
摘要

相似文献

1
FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.FOLFOXIRI方案用于转移性结直肠癌：来自其发源地的批评。
Cancer Lett. 2017 Nov 1;408:71-72. doi: 10.1016/j.canlet.2017.08.025. Epub 2017 Aug 24.
2
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.转移性结直肠癌的 FOLFOXIRI 和贝伐珠单抗初始治疗。
N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.
3
Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer.了解FOLFOXIRI方案以优化转移性结直肠癌的治疗。
Crit Rev Oncol Hematol. 2016 Apr;100:117-26. doi: 10.1016/j.critrevonc.2016.01.020. Epub 2016 Jan 23.
4
Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?FOLFOXIRI联合贝伐单抗应成为转移性结直肠癌的标准一线治疗方案吗？
Oncologist. 2015 Mar;20(3):236-8. doi: 10.1634/theoncologist.2014-0495. Epub 2015 Feb 6.
5
FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.FOLFOXIRI 方案治疗转移性结直肠癌：系统评价和荟萃分析。
Clin Colorectal Cancer. 2017 Dec;16(4):405-409.e2. doi: 10.1016/j.clcc.2017.03.012. Epub 2017 Mar 24.
6
Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).老年转移性结直肠癌患者接受 FOLFOXIRI 与 FOLFIRI 治疗的临床结局：来自希腊肿瘤研究组（HORG）的一项随机 III 期试验的亚组分析。
Crit Rev Oncol Hematol. 2010 Oct;76(1):61-70. doi: 10.1016/j.critrevonc.2009.08.003. Epub 2009 Sep 3.
7
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.三联化疗（FOLFOXIRI）联合贝伐单抗与双联化疗（FOLFOX/FOLFIRI）联合贝伐单抗用于转移性结直肠癌转化治疗的Meta分析
Cell Physiol Biochem. 2018;48(5):1870-1881. doi: 10.1159/000492508. Epub 2018 Aug 9.
8
[A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].[FOLFOXIRI化疗用于转移性结直肠癌一线治疗的综述]
Nihon Rinsho. 2011 Apr;69 Suppl 3:439-45.
9
Case-based discussion for the management of metastatic colorectal cancer.转移性结直肠癌管理的病例讨论
ONS News. 2006;21(8 Suppl):31-2.
10
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.早期肿瘤退缩和深度缓解反应可预测一线化疗联合贝伐珠单抗治疗转移性结直肠癌患者的长期结局：来自西北肿瘤协作组 TRIBE 三期试验的结果。
Ann Oncol. 2015 Jun;26(6):1188-1194. doi: 10.1093/annonc/mdv112. Epub 2015 Feb 23.

引用本文的文献

1
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.UGT1A1 基因多态性与转移性结直肠癌伊立替康化疗的相关性：来自广西壮族自治区的研究。
BMC Gastroenterol. 2020 Apr 7;20(1):96. doi: 10.1186/s12876-020-01227-w.